Valemetostat

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer	2025/02/04	NCT06807632	Phase 1	Recruiting	Memorial Sloan Kettering Cancer Center
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations	2024/10/16	NCT06644768	Phase 1	Recruiting	Daiichi Sankyo
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial	2024/10/09	NCT06632977	Phase 2	Recruiting	Alliance for Clinical Trials in Oncology
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC	2024/03/05	NCT06294548	Phase 1	Not yet recruiting	University of Alabama at Birmingham
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors	2024/02/06	NCT06244485	Phase 1	Recruiting	Daiichi Sankyo
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS	2023/05/30	NCT05879484	Phase 1	Not yet recruiting	National Cancer Institute (NCI)
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma	2023/01/13	NCT05683171	Phase 1	Recruiting	M.D. Anderson Cancer Center
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer	2022/12/01	NCT05633979	Phase 1	Recruiting	M.D. Anderson Cancer Center
Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma	2021/04/13	NCT04842877	Phase 2	Active, not recruiting	The Lymphoma Academic Research Organisation
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)	2021/01/11	NCT04703192	Phase 2	Active, not recruiting	Daiichi Sankyo

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Daiichi Sankyo Presents Breakthrough ENHERTU Data at ASCO 2025 with Two Late-Breaking Phase 3 Trials

a month ago

ENHERTU combined with pertuzumab demonstrated superior progression-free survival compared to standard taxane, trastuzumab and pertuzumab therapy as first-line treatment for HER2 positive metastatic breast cancer in the DESTINY-Breast09 phase 3 trial.

EZH2 Inhibitors Enhance Lymphoma Immunotherapy in Preclinical Models

7 months ago

EZH2 inhibitors, like tazemetostat and valemetostat, enhance T-cell-based immunotherapies against B-cell non-Hodgkin lymphomas in preclinical models.

Valemetostat Shows Promise in Relapsed/Refractory Peripheral T-Cell Lymphoma

8 months ago

A Phase II trial of valemetostat demonstrated a 44% objective response rate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

AI-Powered Research

Premium Access